Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. filings document the regulatory record of a foreign private issuer developing oncology therapies. Its Form 6-K reports furnish financial-results releases, clinical-development updates for vebreltinib (APL-101), material agreements and license matters, related-party convertible-note financing, collaboration updates, and operational-continuity disclosures.
The filing record also covers governance and control procedures, including director appointments and committee composition, auditor changes, registration-statement incorporation, and litigation-related disclosures. These filings place Apollomics' oncology pipeline, capital structure, public-company governance and risk matters into formal SEC-reporting categories.
Apollomics Inc. director Huang Ya-Chi exercised restricted stock units that vested into common equity. On May 17, 2026, 500 Restricted Stock Units vested and were converted into 500 Class A Ordinary Shares at an exercise price of $0.00 per share.
Following this transaction, Huang directly holds 1,000 Class A Ordinary Shares. The RSU grant was previously disclosed, with 500 RSUs vesting on each of February 17, 2026 and May 17, 2026, and an additional 500 RSUs scheduled to vest on each of August 17, 2026 and November 17, 2026.
Apollomics Inc. is amending its Form F-3 shelf registration to register for resale up to 279,775 Class A ordinary shares previously issued under PIPE subscription agreements dated September 2, 2025. The shares are being registered for resale by the selling securityholders to satisfy registration rights.
The prospectus states the PIPE Shares may be sold from time to time at prevailing market prices or negotiated prices through various distribution methods. The filing also discloses 2,196,052 Class A Ordinary Shares outstanding as of April 30, 2026 and includes related corporate, governance and PRC-operational risk disclosures incorporated by reference.
Apollomics Inc. reported full-year 2025 results showing its first revenue of $8.5M, driven by an upfront payment from the LaunXP licensing deal for vebreltinib in parts of Asia. The company sharply cut operating expenses to $19.8M from $55.7M, reducing its net loss to $10.9M (or $7.57 per diluted share) from $53.9M in 2024.
Cash, cash equivalents, bank deposits and money market funds were $3.3M as of December 31, 2025, down from $9.8M a year earlier, despite raising $4.1M via a PIPE in September 2025. The balance sheet showed a total equity deficit of $3.2M, reflecting accumulated losses. Strategically, Apollomics highlighted global Phase 2 development of its lead c-MET inhibitor vebreltinib, Chinese approvals for vebreltinib and PD-L1 antibody APL-502 in multiple indications, and a 2025 turnaround effort under a new management team with substantial cost reductions and resolution of legacy legal and clinical obligations.
Apollomics Inc. files its annual report highlighting significant going‑concern risks and heavy dependence on a single lead drug. The pre‑revenue oncology company reported a net loss of $10.9 million and operating cash outflows of $10.4 million for the year ended December 31, 2025.
Cash and cash equivalents were $3.3 million at year‑end, plus a $2.3 million receivable from LaunXP and a post‑year‑end $2.0 million unsecured convertible bridge loan from its CEO. Management concludes existing resources are insufficient through April 30, 2027, creating material uncertainty about its ability to continue as a going concern.
The business is "substantially dependent" on vebreltinib. The board deferred a planned U.S. NDA for NSCLC with MET exon 14 skipping after determining the current data package was insufficient and enrollment in a new MET‑amplified cohort has been slow. A separate program, uproleselan, suffered a $10.0 million impairment after negative Phase 3 data from its licensor.
The report details restructuring, headcount reduction to 14 employees, and prior and prospective dilution, including a $4.1 million private placement of 1.04 million Class A Ordinary Shares at $3.9317 per share and the CEO’s note that may convert at a discount in a future financing. The company emphasizes numerous clinical, regulatory, financing, and China‑related operational risks.
Apollomics Inc. director Hong-Jung Chen filed an amended initial ownership report detailing current equity holdings. The filing lists 1,000 restricted stock units, each representing one Class A Ordinary Share, with 500 units vesting on June 15, 2026 and 500 on September 15, 2026. Chen also holds options over 2,290 Class A Ordinary Shares at an exercise price of $75.00 per share and options over 2,028 shares at $6.20 per share, plus warrants over 304 underlying shares at an adjusted exercise price of $1,150.00 per full share. Direct holdings also include 3,120 Class A Ordinary Shares.
Apollomics Inc.'s Chief Financial Officer Peter Kuan-How Lin reported an automatic share disposition related to equity compensation. On the vesting of restricted stock units, 3,582 Class A Ordinary Shares were withheld to cover tax obligations at $15.85 per share. After this tax-withholding event, Lin directly holds 12,318 Class A Ordinary Shares. This was not an open-market sale but a routine mechanism tied to RSU vesting.
Apollomics Inc. director Jan Chen-Huan has filed an amended ownership report showing equity awards and share holdings. The filing lists 1,000 Restricted Stock Units, each representing a contingent right to receive one Class A Ordinary Share. These RSUs are scheduled to vest in two equal installments of 500 shares on June 15, 2026 and September 15, 2026. The filing also reports direct ownership of 1,000 Class A Ordinary Shares following the reported positions.
Apollomics Inc. director Tsai Hsien-Shu reports equity holdings consisting of restricted stock units and common shares. The filing shows 1,000 restricted stock units, each representing a contingent right to receive one Class A Ordinary Share at an exercise price of $0.00 per share.
These restricted stock units will vest in two equal installments of 500 shares on June 15, 2026 and September 15, 2026. The filing also lists direct ownership of 1,000 Class A Ordinary Shares following the reported holdings.
Apollomics Inc. Chief Financial Officer LIN PETER KUAN-HOW reported his equity holdings in an amended Form 3. He holds restricted stock units representing 20,000 Class A Ordinary Shares and 15,900 Class A Ordinary Shares directly. The restricted stock units will vest in two equal installments of 10,000 shares each on June 15, 2026 and September 15, 2026.